Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SARS-CoV-2 present significantly longer in stool than in respiratory, serum samples

Key clinical point: Viral clearance should be monitored on the basis of disease severity for COVID-19 patients and stool must be considered as a longer risk for infection.

Major finding: The median duration of virus in the respiratory samples of patients with severe disease (21 days) was significantly longer than in patients with mild disease (14 days; P = .04)

Study details: A retrospective, single-center study of 96 COVID-19 patients; 22 with mild disease and 74 with severe disease.

Disclosures: The study was funded by the China National Mega-Projects for Infectious Diseases and the National Natural Science Foundation of China. The authors reported they had no disclosures.


Zheng S et al. BMJ. 2020;369:m1443.